125 completed, 20 terminated, 13 unknown, 6 recruiting. 175 Phase 3, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 175 | Completed 125, Terminated 20, Unknown 13, Recruiting 6, Active not recruiting 5, Withdrawn 4, Not yet recruiting 2 |
| Phase 2 | 22 | Completed 15, Terminated 3, Unknown 2, Withdrawn 2 |
Follow Bronchitis: new trials by email Literature Review of Bronchitis trials Research Report on Bronchitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease Belumosudil, Best available therapy (BAT) - Chronic Graft Versus Host Disease | Phase 3 | Not yet recruiting | Sanofi | 356 | 2026-09-07 | 2026-09-15 |
| Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients Raphamin, Placebo - Bronchitis, Acute Bronchitis | Phase 3 | Recruiting | Materia Medica Holding | 308 | 2025-12-09 | 2026-06-29 |
| An Efficacy and Safety Study of DFL24498 in the Treatment of AKC DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution - Atopic Keratoconjunctivitis | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 153 | 2025-12-01 | 2026-09-21 |
| Efficacy and Safety of AG2001 in Patients With Acute Bronchitis AG2001, AG20011, AG20012 - Acute Bronchitis | Phase 3 | Not yet recruiting | Ahn-Gook Pharmaceuticals Co.,Ltd | 300 | 2025-11-01 | 2025-09-30 |
| Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis YHP2401, YHR2402, YHR2403 - Acute Bronchitis | Phase 3 | Completed | Yuhan Corporation | 286 | 2025-08-19 | 2026-02-09 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Corporation | 9 | 2025-06-04 | 2026-08-25 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux) - Graft-versus-host Disease (GVHD) | Phase 3 | Recruiting | Incyte Corporation | 572 | 2025-04-02 | 2026-10-22 |
| Hyaluronic Acid Mouthwash as Adjunct Hyaluoric acid mouthwash, Chlorhexidine 0,12% - Gingivitis; Chronic | Phase 3 | Completed | Cairo University | 16 | 2025-02-01 | 2026-01-26 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease INCA034176, Placebo, Corticosteroids - Chronic Graft-versus-host-disease | Phase 3 | Recruiting | Incyte Corporation | 240 | 2025-01-21 | 2026-10-09 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease INCA034176 - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Biosciences Japan GK | 21 | 2024-07-30 | 2026-10-05 |
| A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212 DW5121, DW51211, DW51212 - Acute Bronchitis | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 273 | 2024-03-28 | 2025-07-30 |
| A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. Belumosudil, Placebo, Prednisone - Chronic Graft Versus Host Disease | Phase 3 | Active not recruiting | Sanofi | 260 | 2024-01-23 | 2026-10-16 |
| Efficacy of Vitamin D Supplementation for Children With Bronchiolitis Vitamin D3 - Bronchiolitis | Phase 2 / Phase 3 | Completed | Sohag University | 146 | 2023-04-01 | 2024-10-29 |
| Evaluation of the Efficacy of Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults Azithromycin Oral Tablet, Placebo - Sinusitis, Chronic, Sinus Infection Chronic | Phase 3 | Recruiting | Centre Hospitalier Intercommunal Creteil | 230 | 2022-11-21 | 2025-08-29 |
| Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Sodium Chloride 0.9% Inhl 3Ml - Bronchiolitis, Bronchodilator Agents | Phase 3 | Recruiting | Nemours Children's Clinic | 400 | 2022-07-08 | 2026-05-08 |
| Nebulised 3% Hypertonic Saline in Infants With Acute Bronchiolitis 3% Sodium Chloride, Standard care - Acute Bronchiolitis | Phase 2 / Phase 3 | Completed | Can Tho University of Medicine and Pharmacy | 140 | 2022-06-01 | 2024-08-16 |
| Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis Magnesium Sulfate - Bronchiolitis, Viral | Phase 2 / Phase 3 | Withdrawn | University of Louisville | 2021-07-21 | 2026-05-11 | |
| A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 4710 | 2021-07-14 | 2025-12-17 |
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 3973 | 2021-07-12 | 2026-02-02 |
| Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Seretide, Placebo - Stem Cell Transplant Complications, Respiratory Disease | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 35 | 2021-05-21 | 2025-09-16 |
Showing 20 of 175. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (86) · Bronchitis, Chronic (31) · Bronchiolitis (27) · Pulmonary Disease, Chronic Obstructive (27) · Emphysema (15) · Bronchiolitis Obliterans (12) · Pain (9) · Constipation (8) · Cough (8) · Lymphoma, Follicular (8) · Psoriasis (7) · Leukemia (6) · Respiratory Tract Infections (6) · Hepatitis C (5)
Bronchial Diseases (172) · Lung Diseases (172) · Lung Diseases, Obstructive (172) · Respiratory Tract Diseases (171) · Bronchiolitis (97) · Infections (95) · Pathological Conditions, Signs and Symptoms (92) · Immune System Diseases (88) · Organizing Pneumonia (86) · Bronchiolitis Obliterans (83) · Graft vs Host Disease (82) · Respiratory Tract Infections (78) · Pathologic Processes (54) · Chronic Disease (49)
Azithromycin (9) · aclidinium bromide (9) · Sodium Chloride (8) · Formoterol Fumarate (7) · Saline Solution (7) · tofacitinib (7) · Imatinib Mesylate (6) · Prednisone (5) · Tacrolimus (5) · ibrutinib (5) · Cyclosporine (4) · Levofloxacin (4) · Mycophenolic Acid (4) · Salmeterol Xinafoate (4) · Standard of Care (4)
Pfizer (12) · AstraZeneca (9) · Assistance Publique - Hôpitaux de Paris (6) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · Novartis Pharmaceuticals (6) · Ahn-Gook Pharmaceuticals Co.,Ltd (5) · Incyte Corporation (5) · Baqiyatallah Medical Sciences University (4) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · GlaxoSmithKline (4) · Sumitomo Pharma America, Inc. (4) · Zambon SpA (4) · Gilead Sciences (3) · APT Pharmaceuticals, Inc. (2) · Chiesi Farmaceutici S.p.A. (2)
United States (58) · Germany (38) · Canada (35) · France (34) · United Kingdom (31) · Spain (30) · South Korea (24) · Belgium (21) · Italy (21) · Netherlands (20) · Poland (20) · Australia (19) · Austria (18) · Israel (17) · Hungary (15)
Esther Garcia, MD (7) · Mary Horowitz, MD (2) · Mostafa Ghanei, MD (2) · Paola Castellani, MD (2) · Alan Jackson, MB, BS (1)
PMID 32816215, PMID 26149717, PMID 26233481, PMID 28396102, PMID 28558833, PMID 31827323, PMID 36791280, PMID 38696034, PMID 12563043, PMID 15121942, PMID 16352625, PMID 17261234, PMID 17300356, PMID 17999759, PMID 18668692, PMID 19860762, PMID 20109213, PMID 20347286, PMID 21183326, PMID 21943218, PMID 22147778, PMID 22230731, PMID 22320148, PMID 22645182, PMID 23380743, PMID 23668548, PMID 23679347, PMID 24085591, PMID 24139233, PMID 24229360, PMID 24268590, PMID 24382580, PMID 24410959, PMID 24521787, PMID 24862623, PMID 24881631, PMID 24928639, PMID 25038354, PMID 25404569, PMID 25418186, PMID 25583164, PMID 25756831, PMID 25788164, PMID 25835160, PMID 26051365, PMID 26182309, PMID 26278222, PMID 26286532, PMID 26743093, PMID 26784000
2018 (4), 2015 (3), 2023 (3), 2008 (2), 2014 (2), 2016 (2), U01HL069294 (2), 2019 (1), 2025 (1), R01HL053755 (1), U01AT001908 (1), U01IP000127 (1), U24CA076518 (1)